标题
The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors
作者
关键词
Diabetes mellitus, Fulminant diabetes, Autoimmune diabetes, Immune checkpoint inhibitors side effects, Immunotherapy, Programmed cell death-1 (PD-1), Anti-PD-1, Programmed death ligand 1 (PD-L1), Anti-PD-L1, Pancreas volume, Beta cell pancreatic function, Alpha cell pancreatic function, Exocrine pancreatic function, Autoimmune pancreatitis, Autoimmune generalised lipoatrophy, Autoimmune lipodystrophy
出版物
ACTA DIABETOLOGICA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-08-19
DOI
10.1007/s00592-019-01402-w
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients
- (2019) Marie-Léa Gauci et al. MELANOMA RESEARCH
- Acquired Lipodystrophy Associated with Nivolumab in a Patient with Advanced Renal Cell Carcinoma
- (2019) Camila Kruschewsky Falcao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes
- (2019) Alexandre Jehl et al. DIABETES CARE
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Anti–Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?
- (2018) Lucien Marchand et al. DIABETES CARE
- Diabetes and Blood Glucose Disorders Under Anti-PD1
- (2018) Quentin Magis et al. JOURNAL OF IMMUNOTHERAPY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring
- (2018) Francesco Tassone et al. ACTA DIABETOLOGICA
- Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
- (2018) Lucien Marchand et al. ACTA DIABETOLOGICA
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Autoimmune pancreatitis after nivolumab anti–programmed death receptor-1 treatment
- (2018) Lea Dehghani et al. EUROPEAN JOURNAL OF CANCER
- Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma
- (2017) Matthew A Smith-Cohn et al. Immunotherapy
- Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response
- (2017) Lucien Marchand et al. Journal of Thoracic Oncology
- PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes
- (2017) Moufida Ben Nasr et al. Science Translational Medicine
- A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes
- (2016) Young Kwang Chae et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy
- (2016) Masahide Okamoto et al. Journal of Diabetes Investigation
- Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
- (2016) Jared R. Lowe et al. Journal for ImmunoTherapy of Cancer
- Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes
- (2015) R. Fujisawa et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- The rise, fall, and resurgence of immunotherapy in type 1 diabetes
- (2015) Moufida Ben Nasr et al. PHARMACOLOGICAL RESEARCH
- Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
- (2012) C. J. Greenbaum et al. DIABETES
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
- (2011) Tihamer Orban et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More